Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.

Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating restricted access to the CRETA trial details on ClinicalTrials.gov. This reflects an access issue rather than a substantive update to the study information.SummaryDifference20%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page revision updated the version from v3.6.5 to v3.6.6, signaling a minor update to the record. No substantive changes to the study details are indicated.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page now displays Revision: v3.6.5, replacing the previous v3.6.4, indicating a small update to the page template or content management system.SummaryDifference0.0%

- Check66 days agoChange DetectedThe page revision was updated to v3.6.4, replacing the previous v3.6.3. This indicates a maintenance update to the page rather than a change to study data or functionality.SummaryDifference0.0%

- Check88 days agoChange DetectedThe page's Revision tag has been updated to v3.6.3, replacing the previous v3.6.2. This indicates a minor maintenance update to the site version tag.SummaryDifference0.0%

- Check95 days agoChange DetectedThe revision line on the page was updated from Revision: v3.6.0 to Revision: v3.6.2. This indicates a newer version of the page content.SummaryDifference0.0%

Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.